This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Celgene Acquires Abraxis for $2.9 Billion

SUMMIT, N.J. ( TheStreet) -- Celgene (CELG - Get Report) is acquiring Abraxis BioScience (ABII) for $2.9 billion in cash and stock to expand its cancer drug business, the company announced Wednesday.

Celgene is one of the largest biotech companies in the world, with revenue of $2.7 billion last year coming mainly from drugs like Revlimid used to treat cancers of the blood. By acquiring Abraxis, Celgene gains ownership of a drug used to treat breast cancer patients and expands the company's commercial operations into the solid tumor market.

"The acquisition of Abraxis BioScience is an exceptional strategic fit that will accelerate our strategy of becoming a global leader in oncology," said Bob Hugin, Celgene's CEO, in a statement.

Under terms of the agreement, each Abraxis share will be exchanged for $58 in cash and 0.2617 of a share of Celgene common stock. The deal values Abraxis at $71.93 a share, or a 17% premium over the stock's Tuesday closing price of $61.31. That's based on Celgene's Tuesday closing price of $53.24.

Celgene said the acquisition of Abraxis will be dilutive to adjusted earnings in 2011 and accretive in 2012.

Abraxis markets Abraxane, a reformulation of the chemotherapy drug paclitaxel, as a treatment for metastatic breast cancer patients. Abraxis has also shown potential to treat patients with lung cancer and pancreatic cancer.

In addition to cash and stock, Abraxis shareholders are eligible to receive additional cash payments if Abraxis is approved for lung or pancreatic cancers.

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CELG $120.29 -1.00%
AAPL $129.08 0.48%
FB $79.74 0.98%
GOOG $571.00 2.30%
TSLA $197.27 -3.00%


DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs